share_log

Needham Maintains Buy on NextCure, Lowers Price Target to $4

Benzinga ·  Dec 14, 2023 11:30

Needham analyst Gil Blum maintains NextCure (NASDAQ:NXTC) with a Buy and lowers the price target from $6 to $4.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment